Codexis (CDXS) Stock Price, News & Analysis

Company Overview

Codexis, Inc. is a biotechnology company that develops enzymes and other biocatalytic technologies for use in pharmaceutical and biomanufacturing applications. Its proprietary CodeEvolver protein-engineering platform is designed to improve the performance of naturally occurring enzymes, including their activity, selectivity, stability and production characteristics.

The company works with pharmaceutical and biotechnology companies to develop biocatalysts used in the manufacture of active pharmaceutical ingredients, intermediates and other complex molecules. Codexis also offers enzyme products and related development services intended to support more efficient, selective and potentially lower-impact manufacturing processes, including applications involving small-molecule drugs and emerging therapeutic modalities.

Founded in 2002 and headquartered in Redwood City, California, Codexis serves customers internationally through collaborations, licensing arrangements, research and development programs, and commercial enzyme offerings. The company is led by Stephen D. Dilly, who became president and chief executive officer in 2023.

Key Stats

• Today's Range: $1.26 to $1.32
• 50-Day Range: $1.23 to $1.70
• 52-Week Range: $0.96 to $2.98
• Volume: 691,459 shs
• Average Volume: N/A
• Market Capitalization: $140.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Hold

Codexis Stock Analysis - MarketRank™

Codexis scored higher than 58% of companies evaluated by MarketBeat, and ranked 491st out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Codexis has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Codexis has a consensus price target of $6.50, representing about 407.8% upside from its current price of $1.28.

Amount of Analyst Coverage

Codexis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Codexis are expected to grow in the coming year, from ($0.37) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Codexis is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Codexis is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.69% of the float of Codexis has been sold short.

Short Interest Ratio / Days to Cover

Codexis has a short interest ratio ("days to cover") of 6.31.

Change versus previous month

Short interest in Codexis has recently increased by 2.37%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Codexis does not currently pay a dividend.

Dividend Growth

Codexis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.66

News Sentiment

Codexis has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Codexis this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Codexis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,231.00 in company stock.

Percentage Held by Insiders

3.50% of the stock of Codexis is held by insiders.

Percentage Held by Institutions

78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:CDXS
• CIK: 1200375
• Web: www.codexis.com
• Phone: (650) 421-8100
• Fax: 650-421-8102
• Employees: 146
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Codexis: $6.50
• High Price Target: $8.00
• Low Price Target: $5.00
• Potential Upside/Downside: +407.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $77.68 million
• Price / Sales: 1.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 109,506,000
• Free Float: 105,673,000
• Market Cap: $140.17 million
• Optionable: Optionable
• Beta: 2.55